Alexis M Roth1, Nguyen K Tran2, Ben Cocchiaro3, Allison K Mitchell4, David G Schwartz5, Devon J Hensel6, Janna Ataiants4, Jacob Brenner7, Inbal Yahav8, Stephen E Lankenau4. 1. Department of Community Health and Prevention, Dornsife School of Public Health, Drexel University, Philadelphia, PA, USA. Electronic address: amr395@drexel.edu. 2. Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, PA, USA. 3. Center for Public Health Initiatives, University of Pennsylvania, Philadelphia, PA, USA. 4. Department of Community Health and Prevention, Dornsife School of Public Health, Drexel University, Philadelphia, PA, USA. 5. Information Systems Division, Graduate School of Business, Bar-Ilan University, Ramat-Gan, Israel. 6. Section of Adolescent Medicine, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana; Department of Sociology, Indiana University Purdue University Indianapolis, Indianapolis, Indiana; Center for Sexual Health Promotion, Indiana University, Bloomington, Indiana. 7. Pulmonary, Allergy, & Critical Care Division, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Systems Pharmacology and Translational Therapeutics and Center for Translational Targeted Therapeutics and Nanomedicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 8. Coller School of Management, Tel-Aviv University, Tel-Aviv, Israel.
Abstract
INTRODUCTION: Wearable biosensors have the potential to monitor physiological change associated with opioid overdose among people who use drugs. METHODS: We enrolled 16 individuals who reported ≥ 4 daily opioid use events within the previous 30 day. Each was assigned a wearable biosensor that measured respiratory rate (RR) and actigraphy every 15 s for 5 days and also completed a daily interview assessing drug use. We describe the volume of RR data collected, how it varied by participant characteristics and drug use over time using repeated measures one-way ANOVA, episodes of acute respiratory depression (≤5 breaths/minute), and self-reported overdose experiences. RESULTS: We captured 1626.4 h of RR data, an average of 21.7 daily hours/participant over follow-up. Individuals with longer injection careers and those engaging in polydrug use captured significantly fewer total hours of respiratory data over follow-up compared to those with shorter injections careers (94.7 vs. 119.9 h, p = 0.04) and injecting fentanyl exclusively (98.7 vs. 119.5 h, p = 0.008), respectively. There were 385 drug use events reported over follow-up. There were no episodes of acute respiratory depression which corresponded with participant reports of overdose experiences. DISCUSSION: Our preliminary findings suggest that using a wearable biosensor to monitor physiological changes associated with opioid use was feasible. However, more sensitive biosensors that facilitate triangulation of multiple physiological data points and larger studies of longer duration are needed.
INTRODUCTION: Wearable biosensors have the potential to monitor physiological change associated with opioid overdose among people who use drugs. METHODS: We enrolled 16 individuals who reported ≥ 4 daily opioid use events within the previous 30 day. Each was assigned a wearable biosensor that measured respiratory rate (RR) and actigraphy every 15 s for 5 days and also completed a daily interview assessing drug use. We describe the volume of RR data collected, how it varied by participant characteristics and drug use over time using repeated measures one-way ANOVA, episodes of acute respiratory depression (≤5 breaths/minute), and self-reported overdose experiences. RESULTS: We captured 1626.4 h of RR data, an average of 21.7 daily hours/participant over follow-up. Individuals with longer injection careers and those engaging in polydrug use captured significantly fewer total hours of respiratory data over follow-up compared to those with shorter injections careers (94.7 vs. 119.9 h, p = 0.04) and injecting fentanyl exclusively (98.7 vs. 119.5 h, p = 0.008), respectively. There were 385 drug use events reported over follow-up. There were no episodes of acute respiratory depression which corresponded with participant reports of overdose experiences. DISCUSSION: Our preliminary findings suggest that using a wearable biosensor to monitor physiological changes associated with opioid use was feasible. However, more sensitive biosensors that facilitate triangulation of multiple physiological data points and larger studies of longer duration are needed.
Authors: Sarah Kozey Keadle; Kate A Lyden; Scott J Strath; John W Staudenmayer; Patty S Freedson Journal: Exerc Sport Sci Rev Date: 2019-10 Impact factor: 6.230
Authors: Samantha Colledge; Janni Leung; Sarah Larney; Amy Peacock; Jason Grebely; Matthew Hickman; Evan Cunningham; Adam Trickey; Jack Stone; Peter Vickerman; Louisa Degenhardt Journal: Int J Drug Policy Date: 2019-12-18
Authors: Katie Kanter; Ryan Gallagher; Feyisope Eweje; Alexander Lee; David Gordon; Stephen Landy; Julia Gasior; Haideliza Soto-Calderon; Peter F Cronholm; Ben Cocchiaro; James Weimer; Alexis Roth; Stephen Lankenau; Jacob Brenner Journal: Harm Reduct J Date: 2021-07-23
Authors: David G Schwartz; Janna Ataiants; Alexis Roth; Gabriela Marcu; Inbal Yahav; Benjamin Cocchiaro; Michael Khalemsky; Stephen Lankenau Journal: EClinicalMedicine Date: 2020-08-03
Authors: Daniel Fuller; Emily Colwell; Jonathan Low; Kassia Orychock; Melissa Ann Tobin; Bo Simango; Richard Buote; Desiree Van Heerden; Hui Luan; Kimberley Cullen; Logan Slade; Nathan G A Taylor Journal: JMIR Mhealth Uhealth Date: 2020-09-08 Impact factor: 4.773
Authors: Melissa Perri; Natalie Kaminski; Matthew Bonn; Gillian Kolla; Adrian Guta; Ahmed M Bayoumi; Laurel Challacombe; Marilou Gagnon; Natasha Touesnard; Patrick McDougall; Carol Strike Journal: Harm Reduct J Date: 2021-08-05